149 related articles for article (PubMed ID: 28849200)
21. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
[TBL] [Abstract][Full Text] [Related]
22. Whole Exome Sequencing of Rapid Autopsy Tumors and Xenograft Models Reveals Possible Driver Mutations Underlying Tumor Progression.
Xie T; Musteanu M; Lopez-Casas PP; Shields DJ; Olson P; Rejto PA; Hidalgo M
PLoS One; 2015; 10(11):e0142631. PubMed ID: 26555578
[TBL] [Abstract][Full Text] [Related]
23. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
Lee HW; Lee JI; Lee SJ; Cho HJ; Song HJ; Jeong DE; Seo YJ; Shin S; Joung JG; Kwon YJ; Choi YL; Park WY; Lee HM; Seol HJ; Shim YM; Joo KM; Nam DH
Clin Cancer Res; 2015 Mar; 21(5):1172-82. PubMed ID: 25549722
[TBL] [Abstract][Full Text] [Related]
24. Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer.
Tsoli M; Wadham C; Pinese M; Failes T; Joshi S; Mould E; Yin JX; Gayevskiy V; Kumar A; Kaplan W; Ekert PG; Saletta F; Franshaw L; Liu J; Gifford A; Weber MA; Rodriguez M; Cohn RJ; Arndt G; Tyrrell V; Haber M; Trahair T; Marshall GM; McDonald K; Cowley MJ; Ziegler DS
Cancer Biol Ther; 2018; 19(12):1078-1087. PubMed ID: 30299205
[TBL] [Abstract][Full Text] [Related]
25. IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer.
Zhou H; Qian W; Uckun FM; Wang L; Wang YA; Chen H; Kooby D; Yu Q; Lipowska M; Staley CA; Mao H; Yang L
ACS Nano; 2015 Aug; 9(8):7976-91. PubMed ID: 26242412
[TBL] [Abstract][Full Text] [Related]
26. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract][Full Text] [Related]
27. Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.
Wei L; Chintala S; Ciamporcero E; Ramakrishnan S; Elbanna M; Wang J; Hu Q; Glenn ST; Murakami M; Liu L; Gomez EC; Sun Y; Conroy J; Miles KM; Malathi K; Ramaiah S; Anbarasu A; Woloszynska-Read A; Johnson CS; Conroy J; Liu S; Morrison CD; Pili R
Oncotarget; 2016 Nov; 7(47):76374-76389. PubMed ID: 27823983
[TBL] [Abstract][Full Text] [Related]
28. Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts.
Zhang P; Kovtun IV
J Vis Exp; 2020 Jul; (161):. PubMed ID: 32773766
[TBL] [Abstract][Full Text] [Related]
29. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
[TBL] [Abstract][Full Text] [Related]
30. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.
Young G; Wang K; He J; Otto G; Hawryluk M; Zwirco Z; Brennan T; Nahas M; Donahue A; Yelensky R; Lipson D; Sheehan CE; Boguniewicz AB; Stephens PJ; Miller VA; Ross JS
Cancer Cytopathol; 2013 Dec; 121(12):688-94. PubMed ID: 23893923
[TBL] [Abstract][Full Text] [Related]
31. Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with
Yao YM; Donoho GP; Iversen PW; Zhang Y; Van Horn RD; Forest A; Novosiadly RD; Webster YW; Ebert P; Bray S; Ting JC; Aggarwal A; Henry JR; Tiu RV; Plowman GD; Peng SB
Clin Cancer Res; 2017 Sep; 23(18):5547-5560. PubMed ID: 28611205
[No Abstract] [Full Text] [Related]
32. [A Novel Treatment Strategy for Pancreatic Cancer Based on Gene Profiles].
Hayashi H; Nishihara H
Gan To Kagaku Ryoho; 2016 Nov; 43(11):1326-1331. PubMed ID: 27899773
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
[TBL] [Abstract][Full Text] [Related]
34. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.
Jäger W; Xue H; Hayashi T; Janssen C; Awrey S; Wyatt AW; Anderson S; Moskalev I; Haegert A; Alshalalfa M; Erho N; Davicioni E; Fazli L; Li E; Collins C; Wang Y; Black PC
Oncotarget; 2015 Aug; 6(25):21522-32. PubMed ID: 26041878
[TBL] [Abstract][Full Text] [Related]
35. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
[TBL] [Abstract][Full Text] [Related]
36. Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing.
Li M; Chen L; Qu Y; Sui F; Yang Q; Ji M; Shi B; Chen M; Hou P
Oncotarget; 2017 May; 8(22):36319-36330. PubMed ID: 28422736
[TBL] [Abstract][Full Text] [Related]
37. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
38. Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer.
Bennett CW; Berchem G; Kim YJ; El-Khoury V
Oncotarget; 2016 Oct; 7(43):71013-71035. PubMed ID: 27589834
[TBL] [Abstract][Full Text] [Related]
39. Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach.
Fiorentino M; Gruppioni E; Massari F; Giunchi F; Altimari A; Ciccarese C; Bimbatti D; Scarpa A; Iacovelli R; Porta C; Virinder S; Tortora G; Artibani W; Schiavina R; Ardizzoni A; Brunelli M; Knuutila S; Martignoni G
Oncotarget; 2017 Jan; 8(5):7328-7335. PubMed ID: 27741505
[TBL] [Abstract][Full Text] [Related]
40. Impact of next-generation sequencing on the clinical diagnosis of pancreatic cysts.
Jones M; Zheng Z; Wang J; Dudley J; Albanese E; Kadayifci A; Dias-Santagata D; Le L; Brugge WR; Fernandez-del Castillo C; Mino-Kenudson M; Iafrate AJ; Pitman MB
Gastrointest Endosc; 2016 Jan; 83(1):140-8. PubMed ID: 26253016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
